Suppr超能文献

囊性纤维化的急性肺部恶化。

Acute Pulmonary Exacerbations in Cystic Fibrosis.

机构信息

CFF Therapeutics Development Network Coordinating Center, Department of Pediatrics, Seattle Children's Research Institute, Seattle, Washington.

Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine and Pediatrics, University of Washington School of Medicine, Seattle, Washington.

出版信息

Semin Respir Crit Care Med. 2019 Dec;40(6):792-803. doi: 10.1055/s-0039-1697975. Epub 2019 Oct 28.

Abstract

With the improving survival of cystic fibrosis (CF) patients and the advent of highly effective cystic fibrosis transmembrane conductance regulator therapy, the clinical spectrum of this complex multisystem disease continues to evolve. One of the most important clinical events for patients with CF in the course of this disease is an acute pulmonary exacerbation. Clinical and microbial epidemiology studies of CF pulmonary exacerbations continue to provide important insight into the disease course, prognosis, and complications. This work has now led to a number of large scale clinical trials with the goal of improving the treatment paradigm for CF pulmonary exacerbation. The primary goal of this review is to provide a summary of the pathophysiology, the clinical epidemiology, microbial epidemiology, outcome and the treatment of CF pulmonary exacerbation.

摘要

随着囊性纤维化 (CF) 患者生存率的提高和高效囊性纤维化跨膜电导调节剂治疗的出现,这种复杂的多系统疾病的临床谱仍在不断发展。在 CF 患者的病程中,对 CF 患者最重要的临床事件之一是急性肺部恶化。对 CF 肺部恶化的临床和微生物流行病学研究继续为疾病过程、预后和并发症提供重要的见解。这项工作现在已经导致了一些大型临床试验,目的是改善 CF 肺部恶化的治疗模式。本文的主要目的是总结 CF 肺部恶化的病理生理学、临床流行病学、微生物流行病学、结局和治疗。

相似文献

1
Acute Pulmonary Exacerbations in Cystic Fibrosis.
Semin Respir Crit Care Med. 2019 Dec;40(6):792-803. doi: 10.1055/s-0039-1697975. Epub 2019 Oct 28.
2
Diagnosis and Management of Cystic Fibrosis Exacerbations.
Semin Respir Crit Care Med. 2023 Apr;44(2):225-241. doi: 10.1055/s-0042-1760250. Epub 2023 Feb 6.
3
Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.
Thorax. 2007 Apr;62(4):360-7. doi: 10.1136/thx.2006.060889.
4
Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.
Ann Am Thorac Soc. 2015 May;12(5):708-17. doi: 10.1513/AnnalsATS.201410-493OC.
5
Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis.
Eur Respir J. 2012 Jul;40(1):61-6. doi: 10.1183/09031936.00159111. Epub 2011 Dec 1.
6
Procalcitonin, erythrocyte sedimentation rate and C-reactive protein in acute pulmonary exacerbations of cystic fibrosis.
Clin Respir J. 2018 Apr;12(4):1545-1549. doi: 10.1111/crj.12703. Epub 2017 Sep 19.
7
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Cochrane Database Syst Rev. 2015 Mar 26(3):CD009841. doi: 10.1002/14651858.CD009841.pub2.

引用本文的文献

4
Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis.
Pediatr Pulmonol. 2025 Mar;60(3):e71019. doi: 10.1002/ppul.71019.
6
Treatment of Psychological Symptoms in Patients with Cystic Fibrosis.
J Clin Med. 2024 Sep 28;13(19):5806. doi: 10.3390/jcm13195806.
7
Definitions of pulmonary exacerbation in people with cystic fibrosis: a scoping review.
BMJ Open Respir Res. 2024 Aug 15;11(1):e002456. doi: 10.1136/bmjresp-2024-002456.
8
Robust identification of environmental exposures and community characteristics predictive of rapid lung disease progression.
Sci Total Environ. 2024 Nov 10;950:175348. doi: 10.1016/j.scitotenv.2024.175348. Epub 2024 Aug 6.
10
Cystic fibrosis patient characteristics and healthcare resource utilization in Finland using linked registries.
Heliyon. 2024 Jun 22;10(13):e33439. doi: 10.1016/j.heliyon.2024.e33439. eCollection 2024 Jul 15.

本文引用的文献

3
Development and external validation of 1- and 2-year mortality prediction models in cystic fibrosis.
Eur Respir J. 2019 Sep 5;54(3). doi: 10.1183/13993003.00224-2019. Print 2019 Sep.
4
Mortality in Adults with Cystic Fibrosis Requiring Mechanical Ventilation. Cross-Sectional Analysis of Nationwide Events.
Ann Am Thorac Soc. 2019 Aug;16(8):1017-1023. doi: 10.1513/AnnalsATS.201804-268OC.
5
6
Cluster and CART analyses identify large subgroups of adults with cystic fibrosis at low risk of 10-year death.
Eur Respir J. 2019 Mar 14;53(3). doi: 10.1183/13993003.01943-2018. Print 2019 Mar.
8
Validation of the French 3-year prognostic score using the Canadian Cystic Fibrosis registry.
J Cyst Fibros. 2019 May;18(3):396-398. doi: 10.1016/j.jcf.2018.10.014. Epub 2018 Nov 3.
9
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
N Engl J Med. 2018 Oct 25;379(17):1599-1611. doi: 10.1056/NEJMoa1807119. Epub 2018 Oct 18.
10
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验